Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. - Wikidata - wikimedia - TriplyDB

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

http://www.wikidata.org/entity/Q27851971

about

Update in lung cancer and mesothelioma 2012 Targeted therapies and immunotherapy in non-small-cell lung cancer The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer New strategies in immunotherapy for non-small cell lung cancer Lung cancer biomarkers, targeted therapies and clinical assays Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review The Evolution of Therapies in Non-Small Cell Lung Cancer Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges Systemic and targeted therapies for early-stage lung cancer HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design Targeted therapies in development for non-small cell lung cancer Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC Preclinical mouse cancer models: a maze of opportunities and challenges.Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.CIViC database Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer Mutant HRAS as novel target for MEK and mTOR inhibitors Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.Beyond RAS and BRAF: a target rich disease that is ripe for picking Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy Targeted Therapy in Systemic Sclerosis Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Targeting pathways downstream of KRAS in lung adenocarcinoma.Comparing two assays for clinical genomic profiling: the devil is in the data.nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.

P2860

Q24619675-F4A87110-4550-492C-A1EF-70EB5B2210D7 Q26738986-2B466125-8033-46AD-AA2E-46317CD40093 Q26749110-FCAAA259-EB76-49C3-8407-6B1AE103BAF1 Q26775385-2D295FD5-F801-45B4-8873-B252E68B1D9C Q26775396-066E7474-4617-4D1F-89EE-AE164C27DD91 Q26779725-73B3776F-8720-46A0-9C2A-A91773287302 Q26785713-0057ACDF-4C62-4261-809C-F8043C0FA186 Q26786932-5AB0C99A-BAF7-42CD-A6A1-70BB23A8A788 Q26800833-F5BF2563-F964-446C-9BF0-951F08C1A01D Q26865490-5DD7A7F8-507D-424C-9C46-81418057406D Q26866534-40E4FAF9-E63E-42BF-9BF5-B6DF5BF23E2D Q27003440-33436D82-CDA2-4FA6-965F-1343DC80888C Q27022852-A840F39D-A0CC-4CDB-8CEE-714FAEFA2A06 Q27025970-2CDAB1B8-C33D-4128-9392-C00B1B28469F Q27322080-C18B7BF3-D719-414A-A8BC-8669052E944E Q27345462-6C6957C6-D9AB-481A-9622-02C36511D521 Q27612411-0F4A1D6E-5B00-4970-94E8-9ED41DF18CBA Q27852623-BE60F5FF-99F3-49B0-A29B-E4C2F897F82A Q27853021-B868CB56-2376-4329-B072-81104AED2E48 Q27853084-9453D3F5-0762-4873-AA6C-C5D284F80ED6 Q27853180-B86CD0B4-C048-493B-9CFD-EFD78E73B939 Q27853238-DE493138-FF0F-40E0-9A13-9651B86352C7 Q27853330-52781985-EC3C-4292-8536-BAFAABE72DBD Q28066095-44D40300-4957-4B3B-8E78-A563805D4D1D Q28066868-939D717A-C855-48E8-8549-EB4AF515E2D3 Q28069764-5DD77283-08BD-46FC-8BFE-3BA103DFE21F Q28072943-A3FBFAC2-3ED4-42EE-BA6E-052AE01F6218 Q28083446-3D9B41C8-D798-455B-A6B1-4F86397476A3 Q28260541-5E85822D-D746-4F85-82EA-88F2C13C892F Q28552721-4D60BC23-D922-4ADE-AF70-D3A92552B5F0 Q30278774-A6F7CB65-F5E0-4507-A454-D285DD234736 Q30384829-6CA47E14-66EC-48B0-8EFE-FB92E8539F73 Q30487077-B3370304-0E84-4EA8-B49F-FC942B6E8641 Q30597330-B4B7E349-E55B-4FE2-87D4-6D15AA125935 Q30992076-0EC61787-7B37-4AE0-8359-ED95B7893E30 Q33412928-0D5FF9B9-05EC-442E-9CCF-95884124B6E0 Q33430200-D02A207F-0063-46C7-A04E-691E03EEE4A4 Q33439877-AE682FA6-9E1D-4EE9-9217-3DE96B029AE7 Q33560928-C9C35C4B-163A-4F2F-BD8C-DFE8A04D0EA3 Q33599057-9DF929AC-562B-4AB6-9FF3-34EC9DD026FA

P2860

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

http://www.wikidata.org/entity/Q27851971

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@ast

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@en

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@nl

type

label

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@ast

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@en

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@nl

prefLabel

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@ast

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@en

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@nl

P1433

Q27851971-47D95C3F-D3D1-499A-94EF-D71AE71DC76F

P1476

Q27851971-235E29E0-B3F9-45CB-B260-094E3EFAA894

P2093

Q27851971-090923F1-62BB-4A6D-9C51-1DCEA81B85C8

Q27851971-144D14BA-5884-4AD4-8B1D-0E9B3C1F777A

Q27851971-2FDAE414-96A4-4075-8819-D055C6D3A373

Q27851971-4A92BCA3-2859-4232-AB81-643DC661B597

Q27851971-5600359A-55AB-4B31-A560-D154194C3C69

Q27851971-729E04B1-0567-402A-8F9B-3015E93BA821

Q27851971-C094C9DA-4D67-47BA-80E5-6AC62A13DFCB

Q27851971-C64D8DED-4101-4C5A-B6C4-6C61D230E037

Q27851971-C7EA075B-9D12-4CF6-BED2-B0F6911BA4C7

Q27851971-E933461F-91FB-44CF-B0A8-4FDF8AA53B17

P304

Q27851971-5AC8A2E0-4706-4330-922E-40646670D9D2

P31

Q27851971-6880E973-045C-48FB-A444-142819C9FC60

P3181

Q27851971-41085065-0B98-4ADB-8E84-546D5CBB7525

P356

Q27851971-AF32C11C-8015-4EC0-9675-73CE05288DB5

P433

Q27851971-A5A14F71-70FA-4826-A908-3AAC92D7C8E1

P478

Q27851971-82696279-23C9-4C8B-9152-DD5481D77D54

P50

Q27851971-27CE3972-3B73-4AB6-BF2C-164BA9776840

P577

Q27851971-C6EBF9B3-DAB0-4C32-B037-D56EB3F46F6C

P698

Q27851971-CBA2DEAA-B258-417C-9BE3-42D5260CBB8B

P921

Q27851971-5AF250B5-3C96-4EE6-B65E-E80BE8BCC742

Q27851971-A91F4F40-C070-4DF1-8B6F-5CFE5DA8F742

P3181

P356

S1470-2045(12)70489-8

P1433

The Lancet Oncology

P1476

Selumetinib plus docetaxel for ...... ebo-controlled, phase 2 study.

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Carlos Barrios

http://www.w3.org/2001/XMLSchema#string

Fabio Andre Franke

http://www.w3.org/2001/XMLSchema#string

Gaëlle Jeannin

http://www.w3.org/2001/XMLSchema#string

Ian Smith

http://www.w3.org/2001/XMLSchema#string

Johan Vansteenkiste

http://www.w3.org/2001/XMLSchema#string

José Rodrigues Pereira

http://www.w3.org/2001/XMLSchema#string

Lucio Crinò

http://www.w3.org/2001/XMLSchema#string

Lynda Grinsted

http://www.w3.org/2001/XMLSchema#string

Paul Smith

http://www.w3.org/2001/XMLSchema#string

P304

38-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

560043

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S1470-2045(12)70489-8

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23200175

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial